Get the Daily Brief
Latest Biotech News
Lila Sciences Raises $235M Series A to Build AI-Powered Autonomous Labs
Flagship Pioneering-backed Lila Sciences secured $235 million in Series A funding to advance its vision of scientific superintelligence, integrating artificial intelligence into autonomous...
Innovative AI-Enhanced CRISPR Assistant Accelerates Gene Therapy Research
Stanford Medicine researchers developed CRISPR-GPT, an artificial intelligence copilot designed to assist gene-editing experiment design and execution. By integrating AI into CRISPR workflows,...
AllRock Bio Launches with $65M Series A Focusing on Severe Lung Diseases
AllRock Bio, founded by former CinCor Pharma executives, emerged from stealth with a $65 million Series A to advance a small molecule pan-ROCK inhibitor licensed from Sanofi. The drug candidate...
Carolina Molecular Partners with Astoriom for Molecular Testing and Biobanking
Carolina Molecular announced a strategic partnership with Astoriom to integrate advanced molecular testing services with specialized biospecimen storage solutions. This collaboration offers life...
Boston University Secures $4.5M NIH Grant for Women's Health Research
Boston University received a significant $4.5 million National Institutes of Health grant via the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) program. This five-year...
Bioprocess 5.0: Integrating AI and Automation to Scale Next-Generation Therapies
Industry leaders from Cytiva and Merck KGaA highlight the emergence of Bioprocess 5.0, a new era combining artificial intelligence, advanced automation, and sustainability to enhance biologics and...
Novartis Extends Protein Degrader Partnership: $5.7 Billion Deal with Monte Rosa Therapeutics
Novartis has deepened its collaboration with Monte Rosa Therapeutics by securing exclusive rights and options on molecular glue degraders for immune-mediated diseases in a deal valued at up to...
Phase 3 Setback for aTyr Pharma’s Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma’s lead drug candidate efzofitimod failed to meet its primary endpoint in a Phase 3 trial for pulmonary sarcoidosis, an inflammatory lung disease. The trial measured reduction in...
Lila Sciences Raises $235M Series A to Build AI-Driven Autonomous Research Labs
Flagship Pioneering’s Lila Sciences secured $235 million in Series A funding to develop scientific superintelligence by integrating advanced artificial intelligence into laboratory research...
Deep Learning Toolkit Flexynesis Advances Precision Oncology via Multi-Omics Integration
Researchers at the Max Delbrück Center released Flexynesis, a deep learning toolkit that integrates diverse multi-omics datasets and clinical information to improve diagnosis, prognosis, and...
CSL and VarmX Announce $117M Deal to Advance Phase 3 Blood Clotting Drug
CSL has invested $117 million upfront in Dutch biotech VarmX, obtaining an option to acquire its Phase 3-ready drug candidate poised to reverse anticoagulant effects, such as those from Eliquis,...
South Korea Moves to Boost Biosimilar Approvals with Higher Fees and Faster Reviews
South Korea's Ministry of Food and Drug Safety announced plans to raise application fees for biosimilar drug approvals significantly while expediting review timelines beginning next year. This...
Bionano Genomics Prices $10M Public Offering to Fund Operating Activities
Bionano Genomics has priced a public offering of 5 million shares at $2.00 each, raising approximately $10 million before expenses, with warrants potentially bringing an additional $20 million if...
Enhanced Genomics Expands Series A to $19M to Broaden Therapeutic Pipeline
Enhanced Genomics, a UK-based drug discovery firm utilizing a 3D multiomics platform called GenLink, raised an extended Series A funding round totaling $19 million. The capital will support...
Flexible Single-Cell Transcriptomics Platform Enables Million-Cell Profiling
Parse Biosciences launched the Evercode WT Penta and Penta 384 platforms, enabling whole transcriptome single-cell RNA sequencing at unprecedented scales—up to five million cells and 384 samples...
Biotech Industry Turmoil Leads to Boston Startup Closures and Job Cuts
Amid a challenging funding environment post-pandemic, multiple Boston-area biotech startups have shuttered or downsized, including NextRNA Therapeutics. Despite promising science and prior...
Novartis Expands Molecular Glue Deal With Monte Rosa for Immune Diseases
Novartis has cemented a second collaboration with Monte Rosa Therapeutics, making a $120 million upfront payment for exclusive rights to an undisclosed protein degrader target and options on two...
aTyr Pharma’s Phase 3 Failure in Pulmonary Sarcoidosis and Its Market Impact
aTyr Pharma announced that its lead candidate, efzofitimod, failed to meet the primary endpoint in a Phase 3 trial for pulmonary sarcoidosis, showing no statistically significant steroid dose...
Bionano Genomics Conducts $10M Public Stock Offering
Bionano Genomics has priced a public offering of 5 million common stock shares at $2.00 each, aiming to raise $10 million before expenses, with concurrent offerings of up to 5 million Series E and...
Enhanced Genomics Raises $19M Series A To Expand Drug Discovery Pipeline
Enhanced Genomics, a Cambridge, UK-based drug discovery startup spun out from the Babraham Institute, has closed additional funding to increase its Series A round to $19 million. The firm is...